EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease

Brain Research

Volumn 972, Issue 1-2, 2003, Pages 177-185

  Vorobyov, Vasily V ^a   Schibaev, Nikolai V ^b   Morelli, Micaela ^c   Carta, Anna R ^c  

^a INSTITUTE OF CELL BIOPHYSICS   (Russian Federation)

^b RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cortex; EEG; Priming; Striatum

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA RHYTHM; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; ELECTROENCEPHALOGRAPHY; FREQUENCY ANALYSIS; MALE; MEDIAL FOREBRAIN BUNDLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SOMATOSENSORY CORTEX;

EID: 0037449205     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02528-9     Document Type: Article

References (53)

1. Bagetta G., Corasaniti M.T., Strongoli M.C., Sakurada S., Nisticò G. Behavioral and EcoG spectrum power effects after intraventricular injection of drugs altering dopaminergic transmission in rats. Neuropharmacology. 26:1987;1047-1052.
2. Barone P., Morelli M., Popoli M., Cicarelli G., Campanella G., Di Chiara G. Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation. Neuroscience. 61:1994;867-873.
3. Berardelli A., Rothwell J.C., Thompson P.D., Hallet M. Pathophysiology of bradykinesia in Parkinson's disease. Brain. 124:2001;2131-2146.
4. Berretta S., Parthasarathy H.B., Graybiel A.M. Local release of gabaergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J. Neurosci. 17:1997;4752-4763.
5. Bourne J.A., Fosbraey P., Halliday J. Changes in striatal electroencephalography and neurochemistry induced by kainic acid seizures are modified by dopamine receptor antagonists. Eur. J. Pharmacol. 413:2001;189-198.
6. Calabresi P., Mercuri N.B., Bernardi G. Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vivo analysis. J. Neurophysiol. 63:1990;663-675.
7. Calabresi P., Pisani A., Mercuri N.B., Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19:1996;19-24.
8. Consolo S., Morelli M., Rimoldi M., Giorgi S., Di Chiara G. Increased striatal expression of glutamate decarboxylase 67 after priming of 6-hydroxydopamine-lesioned rats. Neuroscience. 89:1999;183-187.
9. Depoortere H., Decobert M., Honorè L. Drug effects on the EEG of various species of laboratory animals. Neuropsychobiology. 9:1983;244-249.
10. Dimpfel W., Spūler M., Wessel K. Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats. Psychopharmacology. 107:1992;195-202.
11. Dimpfel W., Spuler M. Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission. Psychopharmacology. 101:1990;317-323.
12. Dimpfel W., Spuler M., Koch R., Schatton W. Radioelectroencephalographic comparison of memantine with receptor-specific drugs acting on dopaminergic transmission in freely moving rats. Neuropsychobiology. 18:1987;212-218.
13. Farmer S. Neural rhythms in Parkinson's disease. Brain. 125:2002;1196-1209.
14. Funfgeld E.W. Computerised brain electrical activity findings of parkinson patients suffering from hyperkinetic side effects (hypersensitive dopamine syndrome) and a review of possible sources. J. Neural. Transm. Suppl. 46:1995;351-365.
15. Gal'chenko A.A., Vorobyov V.V. Analysis of electroencephalograms using a modified amplitude-interval algorithm. Neurosci. Behav. Physiol. 29:1999;157-160.
16. Hall R.D., Lindholm E.P. Organization of motor and somatosensory neocortex in the albino rat. Brain Res. 66:1974;23-38.
17. Hellwig B., Häußler S., Lauk M., Guschlbauer B., Köster B., Kristeva-Feige R., Timmer J., Lücking C.H. Tremor-correlated cortical activity detected by electroencephalography. Clin. Neurophysiol. 111:2000;806-809.
18. Henry B., Crossman A.R., Brotchie J.M. Characterisation of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151:1998;334-342.
19. Kropf W., Kuschinsky K. Effects of stimulation of dopamine D1 receptors on the cortical EEG in rats: different influences by a blockade of D2 receptors and by an activation of putative dopamine autoreceptors. Neuropharmacology. 32:1993;493-500.
20. Levy R., Ashby P., Hutchison W.D., Lang A.E., Lozano A.M., Dostrovsky J.O. Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain. 125:2002;1175-1176.
21. Lindefors N., Brodin E., Tossman U., Segovia J., Ungerstedt U. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Exp. Brain Res. 74:1989;527-534.
22. Marsden J.F., Limousin-Dowsey P., Ashby P., Pollack P., Brown P. Subthalamic nucleus, sensorimotor cortex and muscle interrelationships in Parkinson's disease. Brain. 124:2001;378-388.
23. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependence changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 88:1999;1-16.
24. Morelli M. Dopamine-glutamate interaction as studied by combining turning behaviour and c-Fos expression. Neurosci. Behav. Rev. 21:1997;505-510.
25. 1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen. Behav. Brain Res. 79:1996;93-100.
26. 1 receptor-adenylate cyclase complex after priming. Eur. J. Pharmacol. 180:1990;365-367.
27. Morelli M., Fenu S., Garau L., Di Chiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur. J. Pharmacol. 162:1989;329-335.
28. Morelli M., Di Chiara G. Agonist-induced homologous and heterologous sensitization to D-1 and D-2 dependent controversive turning. Eur. J. Pharmacol. 141:1987;101-107.
29. Muller V., Lutzenberger W., Pulvermuller F., Mohr B., Birbaumer N. Investigation of brain dynamics in Parkinson's disease by methods derived from non-linear dynamics. Exp. Brain Res. 137:2001;103-110.
30. Neufeld M.Y., Blumen S., Aitkin I., Parmet Y., Korczyn A.D. EEG frequency analysis in demented and nondemented parkinsonian patients. Dementia. 5:1994;23-28.
31. Nicola S.M., Surmeier J., Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu. Rev. Neurosci. 23:2000;185-215.
32. Nisenbaum E.S., Stricker E.M., Zigmond M.J., Berger T.W. Long-term effects of dopamine-depleting brain lesions on spontaneous activity of type II striatal neurons. Brain Res. 398:1986;221-230.
33. Normand E., Popovici T., Onteniente B., Fellmann D., Piatier-Tonneau D., Auffray C., Bloch B. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in the rat striatal neurons. Brain Res. 439:1988;39-46.
34. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
35. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A Stereotaxic Atlas of the Rat Brain. 1979;Plenum Press, New York.
36. Pezard L., Jech R., Ruzicka E. Investigation of non-linear properties of multichannel EEG in the early stages of Parkinson's disease. Clin. Neurophysiol. 112:2001;38-45.
37. 1 receptor-dependent cyclic AMP production in striatal tissue. Eur. J. Pharmacol. 331:1997;23-26.
38. Pollack A.E., Strauss J. Time dependence and role of N-methyl-D-aspartate glutamate receptors in the priming of D2-mediated behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats. Brain Res. 827:1999;160-168.
39. Pollack A.E., Turgeon S.M., Fink J.S. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats. Neuroscience. 79:1997;79-93.
40. Pontieri F.E., Morelli M., Orzi F., Terenzi R., Di Chiara G. Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. Synapse. 12:1992;255-260.
41. Roth C., Jeanmonod D., Magnin M., Morel A., Achermann P. Effects of medial thalamotomy and pallido-thalamic tractotomy on sleep and waking EEG in pain and Parkinsonian patients. Clin. Neurophysiol. 111:2000;1266-1275.
42. Sebban C., Zhang X.Q., Tesolin-Decros B., Millan M.J., Spedding M. Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br. J. Pharmacol. 128:1999;1045-1054.
43. Segovia J., Tossman U., Herrera M.M., Garcia M.M., Ungerstedt U. Gamma-aminobutyric acid release in the globus pallidus in vivo after 6-hydroxydopamine lesion in the substantia nigra of the rat. Neurosci. Lett. 70:1986;364-368.
44. Soghomonian J.-J., Gonzales C., Chasselet M.-F. Messenger RNAs encoding glutamate-decarboxylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons. Brain Res. 576:1992;68-79.
45. Soikkeli R., Partanen J., Soininen H., Paakkonen A., Riekkinen P. Sr. Slowing of EEG in Parkinson's disease. EEG Clin. Neurophysiol. 79:1991;159-165.
46. Stanzione P., Marciani M.G., Maschio M., Bassetti M.A., Spanedda F., Pierantozzi M., Semprini R., Bernardi G. Quantitative EEG changes in non-demented Parkinson's disease patients before and during l-dopa therapy. Eur. J. Neurol. 3:1996;354-362.
47. Svaloff A., Tesolin B., Sebban C. Effects of apomorphine in quantified electroencephalography in the frontal cortex: changes with dose and time. Neuropharmacology. 27:1988;1313-1317.
48. 1-receptor agonist. Mol. Brain Res. 61:1998;219-223.
49. Verma A., Kulkarni S.K., Nayar U. Effect of D1- and D2-dopamine agonists on neocortical and hippocampal EEG activity of rat brain: modulation of rimcazole effect. Methods Find. Exp. Clin. Pharmacol. 15:1993;515-525.
50. Wang H.C., Lees A.J., Brown P. Impairment of EEG desynchronisation before and during movement and its relation to bradykinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 66:1999;442-446.
51. Wilson C.J. Morphology and synaptic connections of crossed corticostriatal neurons in the rat. J. Comp. Neurol. 263:1987;567-580.
52. Yurek D.M., Randall P.K. Striatal depth EEG reveals postsynaptic activity of striatal neurons following dopamine receptor stimulation and blockade. Neurosci. Methods. 37:1991;81-91.
53. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, 4th edn., Academic Press, San Diego, CA, USA, 1998.